Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease

Saverymuttu, S. H.; Camilleri, Michael; Rees, Helen C.; Lavender, J. P.; Hodgson, H. J. F.; Chadwick, V. S.

doi:10.1016/0016-5085(86)90376-8

Cited by 270 publications

(144 citation statements)

References 15 publications

Supporting

Mentioning

141

Contrasting

Unclassified

Order By: Relevance

“…Endoscopic remission was defined as a score of zero in the endoscopic portion (mucosal appearance) of the DAI and endoscopic improvement was defined as a decrease in the severity of mucosal inflammation (by at least one grade). Histological remission was defined as a grade of zero or one in the severity of histological inflammation according to the scoring system of Saverymuttu et al 25 and histological improvement was defined as a decrease in the severity of histological inflammation (by at least one grade).…”

Section: Evaluation Methodsmentioning

confidence: 99%

“…The endoscopic severity of mucosal inflammation was graded according to endoscopic (mucosal appearance) portion of the DAI; grade 0, normal mucosa or inactive disease; grade 1, mild inflammatory changes (erythema, decreased vascular pattern, mild friability); grade 2, moderate inflammatory changes (marked erythema, absent vascular pattern, friability, erosions); grade 3, severe inflammatory changes (spontaneous bleeding and ulcers). The histological severity of mucosal inflammation was determined according to the scoring system of Saverymuttu et al 25 The system examines the characteristics of enterocyte appearance, the extent of crypt inflammation and the intensity of mononuclear and neutrophic lamina propria inflammation. These four features of inflammation were assessed and each was given a score of 0-3, depending upon the severity of the abnormality.…”

Section: Endoscopic and Histological Examinationsmentioning

confidence: 99%

See 1 more Smart Citation

Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study

Yamamoto¹,

Umegae²,

Kitagawa³

et al. 2004

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYAim: To assess safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis for distal ulcerative colitis. Methods: Granulocyte and monocyte adsorptive apheresis therapy (five aphereses for 5 consecutive weeks) was performed for 30 consecutive patients with active distal ulcerative colitis. Patient compliance, adverse effects and clinical symptoms were regularly assessed. Results: Adverse effects were noted during nine (6%) apheresis sessions in eight patients; slight headache five, transient abdominal pain with tenesmus two, fever (38°C) one and mild liver dysfunction one. None of these adverse effects was serious and all patients could complete five aphereses. Clinical symptoms (stool frequency and consistency, rectal bleeding, tenesmus and mucus in stools) significantly improved after the third apheresis. Clinical remission (normal stool frequency and no rectal bleeding) was achieved in 21 patients (70%) after five aphereses. The median Disease Activity Index score significantly decreased; from 6 [interquartile range (IQR): 4-7] to 2 (IQR: 1-3) (P < 0.0001). Conclusion: In the treatment of active distal ulcerative colitis, granulocyte and monocyte adsorptive apheresis is safe and well-tolerated. Granulocyte and monocyte adsorptive apheresis had a beneficial effect on clinical remission and symptoms. However, randomized-controlled trials would be necessary to assess a definite efficacy of granulocyte and monocyte adsorptive apheresis.

show abstract

Section: Evaluation Methodsmentioning

confidence: 99%

Section: Endoscopic and Histological Examinationsmentioning

confidence: 99%

Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study

Yamamoto¹,

Umegae²,

Kitagawa³

et al. 2004

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…The most affected part of the colon was scored blindly using a standard 12-point histological scoring system. 17 …”

Section: Histopathological Examination and Scoringmentioning

confidence: 99%

Eosinophilia is attenuated in experimental colitis induced in IL-5 deficient mice

Stevceva

Pavli²,

Husband

et al. 2000

Genes Immun

View full text Add to dashboard Cite

Tissue eosinophilia is a feature of idiopathic inflammatory bowel disease and other forms of colonic inflammation but it is not clear whether the role of eosinophils in the disease process is to contribute to tissue damage. Interleukin 5 (IL-5) stimulates production and activation of eosinophils in vitro and enhances immunoglobulin A (IgA) production. As very little is known about the function of IL-5 in the colon, the aim of this study was to assess its role in colonic inflammation. IL-5 deficient mice were studied using the dextran sulphate sodium (DSS)-induced colitis model and the results compared to a congenic IL-5+/+ strain. The absence of IL-5 resulted in reduction of tissue eosinophilia (P Ͻ 0.0001) but was not reflected in differences in the severity of the disease (P Ͼ 0.5) or in the extent of tissue damage in this model of colitis. Numbers of immunoglobulin-containing cells in IL-5 deficient mice were similar to those in the IL-5+ mice. We conclude that the main role of IL-5 in DSS-induced colonic inflammation is to attract a population of eosinophils which do not appear to contribute significantly to the initiation or development of tissue damage in this model of colitis. Genes and Immunity (2000) 1, 213-218.

show abstract

“…Faeces is in direct contact with this inflammed intestinal mucosa, thus making stool is an obvious place for biomarker discovery in IBD [5]. High faecal neutrophil levels have been detected in IBD and may be used as markers of disease activity [6,7].…”

Section: Introductionmentioning

confidence: 99%

“…The faecal excretion of Indium 111-labelled leukocytes is still the golden standard faecal marker of inflammation. Unfortunately, neutrophil counting in faecal specimens is hampered by pre-analytical issues: the sample should be examined within a few hours of its collection [7].…”

Section: Introductionmentioning

confidence: 99%

Faecal leukocyte esterase activity is an alternative biomarker in inflammatory bowel disease

Dumoulin

Biervliet

Vos

et al. 2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Background: Leukocyte cytosolic proteins (e.g., calprotectin) are emerging biomarkers for inflammatory bowel disease. Leukocyte aryl esterase activity has been commonly used for sensitive detection of leukocytes in human body fluids such as urine. Urine test strip results are generally reported in categories. As automated strip readers allow quantitative data to be reported, sensitive quantitative detection of leukocytes in body fluids has become possible. Here, we explored the use of leukocyte esterase as a potential alternative faecal biomarker for inflammatory bowel disease. Methods: We evaluated leukocyte esterase activity in faecal extracts and compared Cobas u 411 (Roche) quantitative reflectance data with calprotectin concentration for 107 routine samples. Stability of leukocyte esterase for trypsin digestion was carried out by adding trypsin to the extract. Incubation occurred at 37 °C for 24 h or 48 h. Results: Reproducibility of the reflectance signal was good (within-run imprecision: 6.1%; between-run imprecision: 6.2%). Results were linear in the range 10

show abstract

Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease

Cited by 270 publications

References 15 publications

Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study

Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study

Eosinophilia is attenuated in experimental colitis induced in IL-5 deficient mice

Faecal leukocyte esterase activity is an alternative biomarker in inflammatory bowel disease

Contact Info

Product

Resources

About